# BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Source: https://onco.cc/trials/nct04752826/  
OnCo record `nct04752826` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in ovarian cancer and melanoma, run by BioInvent International AB, now recruiting.

## Summary

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) is a phase 1/2 interventional study registered as NCT04752826 by BioInvent International AB, with 176 participants planned, started 2021-01-25 and due to reach its primary completion in 2026-12-31. Interventions recorded: BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection. Conditions listed: Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04752826
- Phase: 1/2
- Setting: Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475-D20) in Subjects With Advanced Malignancies
- Sponsor: BioInvent International AB
- Enrolled: 176

## Sources

- ClinicalTrials.gov NCT04752826: https://clinicaltrials.gov/study/NCT04752826

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [BioInvent International](https://onco.cc/companies/bioinvent-international/)

---
JSON: https://onco.cc/api/v1/entities/nct04752826.json